Literature DB >> 9049231

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.

S Bruno1, E Silini, A Crosignani, F Borzio, G Leandro, F Bono, M Asti, S Rossi, A Larghi, A Cerino, M Podda, M U Mondelli.   

Abstract

A prospective study was performed to establish whether infection with specific hepatitis C virus (HCV) genotypes was associated with an increased risk of development of hepatocellular carcinoma (HCC) in cirrhosis. A cohort of 163 consecutive hepatitis C virus antibody (anti-HCV)-positive cirrhotic patients was prospectively evaluated for the development of HCC at 6-month intervals by ultrasound (US) scan and alpha-fetoprotein (AFP) concentration. HCV genotypes were determined according to Okamoto. Risk factors associated with cancer development were analyzed by univariate and multivariate statistics. At enrollment, 101 patients (62%) were infected with type 1b, 48 (29.5%) were infected with type 2a/c, 2 (1.2%) were infected with type 3a, 1 (0.6%) was infected with type 1a, 3 (1.8%) had a mixed-type infection, and, in 8 patients (4.9%), genotype could not be assigned. After a 5- to 7-year follow-up (median, 68 months), HCC developed in 22 of the patients, 19 infected with type 1b and 3 with type 2a/c (P < .005). Moreover, HCC developed more frequently in males (P < .01), patients with excessive alcohol intake (P < .01), those over 60 years of age (P < .02), and in patients who did not receive interferon treatment (P < .02). Multivariate analysis showed that type 1b was the most important risk factor associated with tumor development (odds ratio 6.14, 1.77-21.37 95% confidence interval). Other independent risk factors were older age and male sex. Cirrhotic patients infected with HCV type 1b carry a significantly higher risk of developing HCC than patients infected by other HCV types. The latter may require a less intensive clinical surveillance for the early detection of neoplasia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049231     DOI: 10.1002/hep.510250344

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  73 in total

1.  Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study.

Authors:  A R Osella; L Sonzogni; A Cavallini; L Foti; V Guerra; A Di Leo; M U Mondelli; G Misciagna; E M Silini
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis.

Authors:  C Chapoutot; M Esslimani; Z Joomaye; J Ramos; P Perney; C Laurent; P Fabbro-Peray; D Larrey; J Domergue; F Blanc
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

Review 3.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

4.  Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

Authors:  A Gramenzi; P Andreone; S Fiorino; C Cammà; M Giunta; D Magalotti; C Cursaro; C Calabrese; V Arienti; C Rossi; G Di Febo; M Zoli; A Craxì; G Gasbarrini; M Bernardi
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

5.  Prevention of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

6.  Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients.

Authors:  M G Rumi; F De Filippi; C La Vecchia; M F Donato; S Gallus; E Del Ninno; M Colombo
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 7.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 8.  Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.

Authors:  Gianni Testino; Paolo Borro
Journal:  World J Hepatol       Date:  2013-10-27

9.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

10.  Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein.

Authors:  Satoshi Ogata; Ruth Huab Florese; Motoko Nagano-Fujii; Rachmat Hidajat; Lin Deng; Yonson Ku; Seitetsu Yoon; Takafumi Saito; Sumio Kawata; Hak Hotta
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.